Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Variability and PK/PD of inhaled human insulin (Dance 501) in adults with type 1 diabetes mellitus
2015-003737-95Phase 2Completed
- Sponsor
- Aerami Therapeutics
- Start
- Sep 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Dance-501 in diabetes mellitus type 1 (T1D), sponsored by Aerami Therapeutics. Primary endpoint: Inter- and intra-subject variability in insulin exposure and glucose infusion response. Started Sep 2018; status: completed.
02
Drugs
Dance-501
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2015-003737-95.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003737-95.